Training Experience Required
We seek a highly motivated fellow to work in clinical and translational research at one of our main research groups, such as Gastrointestinal and Endocrine Tumor Group, Breast Cancer Group, Early Clinical Drug Development Group and Experimental Therapeutics Group, among others. Prior experience in Clinical Research will be positively valued. Fellows dealing with patients will need the ability to communicate in Spanish. Written and spoken English are also required for interaction with study sponsors and investigators.
The Vall d’Hebron Institute of Oncology (VHIO) is a leading comprehensive cancer center of excellence where its scientists and research physicians adopt purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer. VHIO’s pioneering model programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
The Vall d´Hebron University Hospital (HVH) is one of the largest hospitals in Spain. The Department of Medical Oncology works on providing patient care and on cutting-edge scientific clinical and basic research, with a clear focus on Translational Oncology. The interaction between Clinical Research and Lab research stimulates the development of new clinical and research opportunities. At the Department of Medical Oncology of HVH both basic and clinical researchers share a vision on Translational Oncology. Organized into multidisciplinary and integrated teams, Vall d’Hebron physician-scientists closely collaborate with VHIO’s researchers. Translational science and clinical research are therefore tightly connected, accelerating the bench-bedside-bed cycle of knowledge.
- Early development and antitumoral innovative treatments.
- New clinical trial designs including combinations and repositions of drugs.
- Identification of prognostic, predictive and response biomarkers of different cancer types.
- Study of sensibility mechanisms and primary or acquired resistance (treatments).
- Preclinic sophisticated models for the experimental study and for the disease monitoring.
- The use of the Big Data and Artificial Intelligence for the implementation of new clinical tools.
- Identification of new molecular cancer subtypes.
At VHIO and HUVH, we believe in cementing strong collaborations between the tumor-specific units, translational research laboratories, and our core technologies.
VHIO is located within the Vall d’Hebron Barcelona Hospital Campus, facilitating the closely collaboration of our researchers with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected with promotes superb interaction and teamwork.
In addition to our renowned expertise in early clinical drug development and clinical trials design, we also pioneer biomarker development (CTC, Pharmacodynamics, etc.), generate and develop patient-derived xenografts, and perform molecular analyses of tumors for treatment selection. Our institution provides all the essential facilities and technologies for translational research, with various groups focused on cancer-stem cells, cell-signaling, resistance to targeted therapies, genomics, and molecular oncology.
Last update: November 2020